Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Receives Notice of Allowance on Patent Application Covering Delivery Tech

Premium

Arrowhead Research this week announced that it has received a notice of allowance from the US Patent and Trademark Office that it will be granted a patent on an application covering its dynamic polyconjugate delivery technology.

The patent application, No. 20120165393, is entitled “Peptide-based In Vivo siRNA Delivery System” and claims the targeted delivery of RNAi oligos to hepatocytes when administered along with co-targeted melittin delivery peptides.

The peptides, the patent application indicates, enable cellular membrane penetration.

The patent application, Arrowhead noted, specifically covers the delivery technology being used with the company’s preclinical hepatitis B therapy ARC-520, which is slated to enter phase I testing this year (GSN 2/14/2013).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more